Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TACE combined with toripalimab and metronomic chemotherapy for advanced hepatocellular carcinoma after sorafenib failure
ChiCTR2000031692Phase 2Not yet recruiting
- Sponsor
- The Seventh Affiliated Hospital, Sun Yat-Sen University
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by The Seventh Affiliated Hospital, Sun Yat-Sen University. Primary endpoint: Overall survival. Planned start May 2020; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000031692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031692.